Bayer: China approves liver cancer drug.
(CercleFinance.com) - The Chinese Food and Drug Administration has approved Bayer's Stivarga tablets for the second-line treatment of patients with hepatocellular carcinoma, the German pharmaceuticals group said on Wednesday.
The company points out that data from a pivotal Phase III study showed that Stivarga provided a clinically meaningful improvement in overall survival rates, with a median of 10.6 months versus 7.8 months for placebo.
Liver cancer - a disease that is more difficult to treat than other cancers - has 466,000 new cases diagnosed in China each year, and 422,000 deaths.
Stivarga has already been approved in China for the treatment of metastatic colorectal cancer and gastrointestinal stromal tumours.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The company points out that data from a pivotal Phase III study showed that Stivarga provided a clinically meaningful improvement in overall survival rates, with a median of 10.6 months versus 7.8 months for placebo.
Liver cancer - a disease that is more difficult to treat than other cancers - has 466,000 new cases diagnosed in China each year, and 422,000 deaths.
Stivarga has already been approved in China for the treatment of metastatic colorectal cancer and gastrointestinal stromal tumours.
Copyright (c) 2017 CercleFinance.com. All rights reserved.